Development of new antituberculosis drugs from natural productsFootnote^†

^†This work is a translation of an original work in Japanese in the Japan Society for Bioscience, Biotechnology, and Agrochemistry http://doi.10.1271/kagakutoseibutsu.54.37.

References

• Burg RW, Miller BM, Baker EE, et al. Avermectins, new family of potentanthelmintic agents: producing organism and fermentation. J Antimicrob Chemother. 1979;15:361.10.1128/AAC.15.3.361
   Web of Science ®Google Scholar
• Tu YY, Ni MY, Zhong YR, et al. Studies on the constituents of Artemisia annua L. Yao Xue Xue Bao. 1981;16:366.
   PubMedGoogle Scholar
• Global TB control WHO report 2014.
   Google Scholar
• Global report: UNAIDS report on the global AIDS epidemic 2013.
   Google Scholar
• Igarashi M, Takahashi Y. Developmental status of new antituberculous drugs. Nihon Rinsho. 2011;69:1482–1488.
   PubMedGoogle Scholar
• Nuermberger EL, Yoshimatsu T, Tyagi S, et al. Moxifloxacin-containing regimen greatly reduces time to culture conversion in murine tuberculosis. Am J Respir Crit Care Med. 2004;169:421–426.10.1164/rccm.200310-1380OC
   PubMed Web of Science ®Google Scholar
• Rustomjee R, Lienhardt C, Kanyok T, et al. A Phase II study of the sterilising activities of ofloxacin, gatifloxacin and moxifloxacin in pulmonary tuberculosis. Int J Tuberc Lung Dis. 2008;12:128–138.
   PubMed Web of Science ®Google Scholar
• Cynamon M, Sklaney MR, Shoen C. Gatifloxacin in combination with rifampicin in a murine tuberculosis model. J Antimicrob Chemother. 2007;60:429–432.10.1093/jac/dkm200
   PubMed Web of Science ®Google Scholar
• Disratthakit A, Doi N. In vitro activities of DC-159a, a novel fluoroquinolone, against Mycobacterium species. Angew Chem Int Ed. 2010;54:2684–2686.10.1128/AAC.01545-09
   Web of Science ®Google Scholar
• Alcalá L, Ruiz-Serrano MJ, Pérez-Fernández Turégano C, et al. In vitro activities of linezolid against clinical isolates of Mycobacterium tuberculosis that are susceptible or resistant to first-line antituberculous drugs. Antimicrob Agents Chemother. 2003;47:416–417.10.1128/AAC.47.1.416-417.2003
   PubMed Web of Science ®Google Scholar
• Williams KN, Stover CK, Zhu T, et al. Promising antituberculosis activity of the oxazolidinone PNU-100480 relative to that of linezolid in a murine model. Antimicrob Agents Chemother. 2009;53:1314–1319.10.1128/AAC.01182-08
   PubMed Web of Science ®Google Scholar
• Balasubramanian V, Solapure S, Iyer H, et al. Bactericidal activity and mechanism of action of AZD5847, a novel oxazolidinone for treatment of tuberculosis. Antimicrob Agents Chemother. 2014;58:495–502.10.1128/AAC.01903-13
   PubMed Web of Science ®Google Scholar
• Nikonenko BV, Protopopova M, Samala R, et al. Drug therapy of experimental tuberculosis (TB): improved outcome by combining SQ109, a new diamine antibiotic, with existing TB drugs. Antimicrob Agents Chemother. 2007;51:1563–1565.10.1128/AAC.01326-06
   PubMed Web of Science ®Google Scholar
• Andries K, Verhasselt P, Guillemont J, et al. A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis. Science. 2005;307:223–227.10.1126/science.1106753
   PubMed Web of Science ®Google Scholar
• Diacon AH, Pym A, Grobusch M, et al. The diarylquinoline TMC207 for multidrugresistant tuberculosis. N Eng J Med. 2009;360:2397–2405.10.1056/NEJMoa0808427
   PubMed Web of Science ®Google Scholar
• Jones D, Metzger HJ, Schatz A, et al. Control of Gram-negative bacteria in experimental animals by streptomycin. Science. 1944;100:103–105.
   PubMedGoogle Scholar
• Umezawa H, Ueda M, Maeda K, et al. Production and isolation of a new antibiotic: kanamycin. J Antibiot. 1957;10:181–188.
   PubMed Web of Science ®Google Scholar
• Price KE, Pursiano TA, DeFuria MD. Activity of BB-K8 (amikacin) against clinical isolates resistant to one or more aminoglycoside antibiotics. Antimicrob Agents Chemother. 1974;5:143–152.10.1128/AAC.5.2.143
   PubMed Web of Science ®Google Scholar
• Kurosawa H. The isolation of an antibiotic produced by a strain of streptomyces K-300. Yokohama Med Bull. 1952;3:386–399.
   PubMedGoogle Scholar
• Herr EB, Redstone MO. Chemical and physical characterization of capreomycin. Ann. N. Y. Acad. Sci. 1966;135:940–946.
   PubMed Web of Science ®Google Scholar
• Sensi P, Margalith P, Timbal MT. Rifomycin, a new antibiotic; preliminary report. Farmaco Sci. 1959;14:146–147.
   PubMedGoogle Scholar
• Maeda K, Osato T, Umezawa H. A new antibiotic, azomycin. J Antibiot. 1953;6:182.
   PubMedGoogle Scholar
• Singh R, Manjunatha U, Boshoff HI, et al. PA-824 kills nonreplicating Mycobacterium tuberculosis by intracellular NO release. Science. 2008;322:1392–1395.10.1126/science.1164571
   PubMed Web of Science ®Google Scholar
• Stover CK, Warrener P, VanDevanter DR, et al. A small-moleculenitroimidazopyran drug candidate for the treatment of tuberculosis. Nature. 2000;405:962–966.10.1038/35016103
   PubMed Web of Science ®Google Scholar
• Dawson R, Diacon AH, Everitt D, et al. Efficiency and safety of the combination of moxifloxacin, pretomanid (PA-824), and pyrazinamide during the first 8 weeks of antituberculosis treatment: a phase 2b, open-label, partly randomised trial in patients with drug-susceptible or drug-resistant pulmonary tuberculosis. Lancet. 2015;385:1738–1747.10.1016/S0140-6736(14)62002-X
   PubMed Web of Science ®Google Scholar
• http://www.tballiance.org/pipeline/pipeline.php.
   Google Scholar
• Matsumoto M, Hashizume H, Tomishige T, et al. OPC-67683, a nitro-dihydroimidazooxazole derivative with promising action against tuberculosis in vitro and in mice. PLoS Med. 2006;3:e446.
   PubMed Web of Science ®Google Scholar
• Igarashi M, Nakagawa N, Doi N, et al. Caprazamycin B, a novel anti-tuberculosis antibiotic, from Streptomyces sp. J Antibiot. 2003;56:580–583.10.7164/antibiotics.56.580
   PubMed Web of Science ®Google Scholar
• Isono K, Uramoto M, Kusakabe H, et al. Liposidomycins: novel nucleoside antibiotics which inhibit bacterial peptidoglycan synthesis. J Antibiot. 1985;38:1617–1621.10.7164/antibiotics.38.1617
   PubMed Web of Science ®Google Scholar
• Takahashi Y, Igarashi M, Miyake T, et al. Novel semisynthetic antibiotics from caprazamycins A-G: caprazene derivatives and their antibacterial activity. J Antibiot. 2003;66:171–178.
   Web of Science ®Google Scholar
• Ishizaki Y, Hayashi C, Inoue K, et al. Inhibition of the first step in synthesis of the mycobacterial cell wall core, catalyzed by the GlcNAc-1-phosphate transferase WecA, by the novel caprazamycin derivative CPZEN-45. J Biol Chem. 2013;288:30309–30319.10.1074/jbc.M113.492173
   PubMed Web of Science ®Google Scholar
• Miyake T, Takahashi, Y, Igarashi M. Synthesis and activity of CPZEN-45, a new antituberculous drug candidate. 235th ACS National Meet: CARB. 2008;104.
   Google Scholar
• Brötz-Oesterhelt H, Beyer D, Kroll HP, et al. Dysregulation of bacterial proteolytic machinery by a new class of antibiotics. Nat Med. 2005;11:1082–1087.10.1038/nm1306
   PubMed Web of Science ®Google Scholar
• Raju RM, Unnikrishnan M, Rubin DH, et al. Mycobacterium tuberculosis ClpP1 and ClpP2 function together in protein degradation and are required for viability in vitro and during infection. PLoS Pathog. 2012;8:e1002511.10.1371/journal.ppat.1002511
   PubMed Web of Science ®Google Scholar
• Renner MK, Shen YC, Cheng XC, et al. Cyclomarins A-C, new antiinflammatory cyclic peptides produced by a marine bacterium (Streptomyces sp.). J Am Chem Soc. 1999;121:11273–11276.10.1021/ja992482o
   Web of Science ®Google Scholar
• Schmitt EK, Riwanto M, Sambandamurthy V, et al. The natural product cyclomarin kills Mycobacterium tuberculosis by targeting the ClpC1 subunit of the caseinolytic protease. Angew Chem Int Ed Engl. 2011;50:5889–5891.10.1002/anie.v50.26
   PubMed Web of Science ®Google Scholar
• Kaku R. Studies on the antitubercular activity of a new antibiotic, ilamycin. 1. Antitubercular activity of water-insoluble ilamycin. J Antibiot B. 1963;16:93–98.
   PubMedGoogle Scholar